Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.

Drug Development: Perspective and Strategy

submitted by: alex01

R. Ruffolo, PhD - Wyeth’s pipeline has 11 potential anti-Alzheimer drugs, including two vaccines and two biotech products. Ruffolo defines breakthrough therapy and the “learn and confirm” concept in clinical trials.